Zelira Therapeutics Limited-HOPE® 1 SPV Secures US$33.0 million Funding
Zelira Therapeutics Limited (ASX: ZLD) released a price-sensitive announcement confirming that its HOPE® 1 special purpose vehicle has signed definitive agreements to raise US$32.98 million before costs. Following completion, ThirdGate Capital will hold a 50.0% fully diluted interest in HOPE® 1 SPV, with Zelira retaining a 39.7% interest. The transaction implies a post-money valuation of US$65.96 million for the SPV and a post-money valuation of Zelira’s interest at approximately US$26.19 million. The funding supports the advancement of HOPE® 1 through the US FDA regulatory pathway, following a successful Pre-IND meeting in which the FDA confirmed the proposed clinical plan and recognised Phelan-McDermid Syndrome as a rare disease. This enables Zelira to pursue Orphan Drug Designation and progress towards IND submission and first-in-human clinical trials. The capital raise represents a significant validation of the HOPE® program and materially strengthens Zelira’s development pathway.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Zelira Therapeutics Limited-HOPE® 1 SPV Secures US$33.0 million Funding
Zelira Therapeutics Limited (ASX: ZLD) released a price-sensitive announcement confirming that its HOPE® 1 special purpose vehicle has signed definitive agreements to raise US$32.98 million before costs. Following completion, ThirdGate Capital will hold a 50.0% fully diluted interest in HOPE® 1 SPV, with Zelira retaining a 39.7% interest. The transaction implies a post-money valuation of US$65.96 million for the SPV and a post-money valuation of Zelira’s interest at approximately US$26.19 million. The funding supports the advancement of HOPE® 1 through the US FDA regulatory pathway, following a successful Pre-IND meeting in which the FDA confirmed the proposed clinical plan and recognised Phelan-McDermid Syndrome as a rare disease. This enables Zelira to pursue Orphan Drug Designation and progress towards IND submission and first-in-human clinical trials. The capital raise represents a significant validation of the HOPE® program and materially strengthens Zelira’s development pathway.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au